Tranexamic Acid Inhibits Fibrinolysis, Shortens the Bleeding Time and Improves Platelet Function in Patients with Chronic Renal Failure

Summary

Background: A defect in platelet function is the main determinant of the prolonged bleeding time in chronic renal failure (CRF). We previously reported a significant correlation between platelet abnormalities and elevated plasma markers of plasmin and thrombin generation. Our aim was to explore the effect of inhibiting both plasmin action with tranexamic acid (TA) and thrombin production with low molecular weight heparin (LMWH), on the bleeding time (BT) and platelet function in patients with CRF. Methods: 37 patients with CRF (mean creatinine 8.6 ± 4.4 mg/dl) under conservative treatment, with prolonged BT, entered this study and received TA during 6 days, with (n = 24) and without LMWH (n = 13). BT, platelet aggregation/secretion, platelet granule contents, von Willebrand factor and parameters of coagulation and fibrinolysis were recorded before and at the end of treatment. Results: The BT was shortened in 26/37 (67%) patients. This effect was associated with significant improvement of platelet aggregation and secretion, with decrease to a normal range of fibrin/fibrinogen degradation products, mild increase in plasmin-antiplasmin complexes and pronounced reduction of circulating plasminogen. No differences were seen among patients with or without LMWH. No serious side effects or complications were observed. Interpretation: These findings indicate that the activation of fibrinolysis plays a significant role in the defect of primary hemostasis in patients with CRF. Inhibition of plasmin activity with TA shortens the BT and improves platelet function in the majority of patients with severe disease.

• References

• 1 Deykin D. Uremic bleeding. Kidney Int 1983; 24: 698-705.
• 2 Remuzzi G. Bleeding in renal failure. Lancet 1988; 1: 1205-8.
• 3 George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Eng J Med 1991; 324: 27-39.
• 4 Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107-17.
• 5 Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-96.
• 6 Gordge MP, Neild GH. Platelet function in uremia. Platelets 1991; 2: 115-23.
• 7 Mezzano D, Tagle R, Panes O, Pérez M, Downey P, Muñoz B, Aranda E, Barja P, Thambo S, González F, Mezzano S, Pereira J. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76: 312-21.
• 8 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-61.
• 9 Cadroy Y, Pourrat J, Baladre M-F, Saivin S, Houin G, Montastruc J-L, Vernier I, Boneu B. Delayed elimination of enoxaparine in patients with chronic renal failure. Thromb Res 1991; 63: 385-90.
• 10 Di Minno G, Martínez J, McKean M, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552-9.
• 11 Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981; 673: 75-85.
• 12 Markus G, Priore RL, Wissler FC. The binding of tranexamic acid to native (Glu) and modified (Lys) human plasminogen and its effect on conformation. J Biol Chem 1979; 254: 1211-6.
• 13 Horrow JC, Hlavacek J, Strong MD, Collier W, Brodsky I, Goldman SM, Goel IP. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990; 99: 70-4.
• 14 Pasqua JJ, Pizzo SV. The role of ligand-ligand interactions in competition by fibrinogen and fibrin degradation products for fibrinogen binding to normal platelets. Bioch Biophys Acta 1983; 757: 282-7.
• 15 Culasso DE, Donati MB, de Gaetano G, Vermylen J, Verstraete M. Inhibition of human platelet aggregation by plasmin digests of human and bovine fibrinogen preparations: role of contaminating factor VIII-related material. Blood 1974; 44: 169-75.
• 16 Adelman B, Michelson AD, Greenberg J, Handin RI. Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood 1986; 68: 1280-4.
• 17 Sloand EM, Sloand JA, Prodouz K, Klein HG, Yu MW, Harvath L, Fricke W. Reduction of platelet glycoprotein Ib in uraemia. Br J Haematol 1991; 77: 375-81.
• 18 Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994; 83: 404-14.
• 19 Benigni A, Boccardo P, Galbusera M, Monteagudo J, De Marco L, Remuzzi G, Ruggeri ZM. Reversible activation of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993; 22: 668-76.
• 20 Gawaz MP, Dobos G, Späth M, Schollmeyer P, Gurland HJ, Mujais SK. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994; 5: 36-46.
• 21 Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-5.
• 22 Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; 2: 1227-9.
• 23 Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Eng J Med 1980; 303: 1318-22.
• 24 Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Eng J Med 1983; 308: 8-12.
• 25 Watson AJS, Keogh JAB. Effect od 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron 1982; 32: 49-52.
• 26 Soslau G, Schwartz AB, Putatunda B, Conroy JD, Parker J, Abel RF, Brodsky I. Desmopressin-induced improvement in bleeding times in chronic renal failure patients correlates with platelet serotonin uptake and ATP release. Am J Med Sci 1990; 299: 372-9.
• 27 Vicente V, Alberca I, Macías JF, López Borrasca A. DDAVP in uremia. Nephron 1984; 36: 145-6.
• 28 Zeigler ZR, Megaludis A, Fraley DS. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol 1992; 39: 90-5.
• 29 Alarcón F, Mezzano D, Vial S, Pereira J. Efecto de la 1-deamino-8-D-arginina vasopresina (DDAVP) sobre el tiempo de sangría en pacientes urémicos. Rev Med Chile 1985; 113: 763-8.
• 30 Liu YK, Kosfeld RE, Marcum SG. Treatment of uraemic bleeding with conjugated oestrogen. Lancet 1984; 2: 887-90.
• 31 Livio M, Mannucci PM, Vigano G, Mingardi G, Lombardi R, Mecca G, Remuzzi G. Conjugated estrogens for the management of bleeding associated with renal failure. N Eng J Med 1986; 315: 731-5.
• 32 Zoja C, Noris M, Corna D, Vigano G, Perico N, de Gaetano G, Remuzzi G. L-arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. Lab Invest 1991; 65: 479-83.
• 33 Lindoff C, Rybo G, Ästedt B. Treatment with tranexamic acid during pregnancy, and the risk of thromboembolic complications. Thromb Haemost 1993; 70: 238-40.
• 34 Vujkovac B, Lavre J, Sabovic M. Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialysis patient. Am J Kidney Dis 1998; 31: 536-8.
• 35 Demarmels Biasiutti F, Sulzer I, Stucki B, Wuillemin WA, Furlan M, Laemmle B. Is plasminogen deficiency a thrombotic risk factor? A study of 23 thrombophilic patients and their family members. Thromb Haemost 1998; 80: 167-70.